Status:
UNKNOWN
TReatment by Insulin Continuous Infusion in Type 2 DIAbetes
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Diabetes
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of the TRICIDIA2 study is to compare two modalities of administration of insulin. In our future study, the investigators wish to study if the treatment by continuous infusion of insulin impro...
Detailed Description
We wish to use before and after treatment the classic tools of measure of insulinosensitivity / the euglycemic hyperinsulinemic clamp associated with a measure of the insulinosecretion thanks to a tes...
Eligibility Criteria
Inclusion
- age \> 18 years old
- type 2 diabete patient with insuline basal/bolus treatment for at least 6 months
- Doses of insuline \> 0,7 U/Kg/j
- HbA1c ≥ 7,5%
- without ADO for at least 4 weeks (sulfamides, Incrétines, glinides, acarbose) except the metformine
- BMI ≥ 28,5 kg/m²
- clinical diagnostique of diabetes for at least 10 ans
- Patient must be able to Realize an automonitoring and to manage the functioning of an insulin pump.
Exclusion
- glitazone treatment less than 3 month before inclusion
- Patient with an untreated by the laser proliferative ischemic retinopathy
- BMI \< 28,5 kg/m²
- Pacemaker (CI IRM)
- Presence of implantable material (CI IRM)
- Pregnancy, breast-feeding
- Practices of violent sports
- Professional extreme environment of cold or heat
- Serious psychiatric diseases physical and/or psychiatric Incapacitated medically significant
- Poor sanitation
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2015
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01889914
Start Date
January 1 2012
End Date
September 1 2015
Last Update
July 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU
Dijon, France, 21000